Table 2.
Final Parameter Estimates for Rifampicin Population PK Model
| Parameter | Estimate | RSE, % |
|---|---|---|
| CL/F,a L/h | 19.6 | 2.01 |
| V/F,a L | 49.3 | 2.62 |
| MTT,b h | 2.06 | 2.36 |
| Covariate effects on CL/F, % | ||
| Asian relative to Black/mixed race | −10.1 | 21.9 |
| Female relative to male | −22.9 | 15.5 |
| Covariate effects on V/F, % | ||
| Female relative to male | −20.7 | 17.2 |
| Interindividual variability,c % | ||
| IIV CL/F | 44.8 | 7.10 |
| IIV V/F | 32.1 | 25.6 |
| IIV MTT | 57.4 | 3.50 |
| Correlation,c % | ||
| CL/F-V/F | 50.5 | 3.49 |
| CL/F-MTT | 76.9 | 2.18 |
| V/F-MTT | 57.5 | 2.23 |
| εprop in log scale | 0.256 | 18.7 |
Abbreviations: CL/F, apparent clearance; CV, coefficient of variation; IIV, interindividual variability; MTT, mean transit time; PK, pharmacokinetics; RSE, relative standard error; V/F, apparent volume of distribution; εprop, proportional error.
aThe parameters CL/F and V/F were allometrically scaled using body weight (WT) and were described by: CL-WT cov = (WT/70)0.75; V-WT cov = (WT/70)1.
bThe number of transit compartments is 4.
cIIV CL/F, IIV V/F, correlation CL/F-V/F, correlation CL/F-MTT, and correlation V/F-MTT are described as CV%.